Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome

Clinical Biochemistry

Volumn 46, Issue 16-17, 2013, Pages 1655-1659

  Eggers, Kai M ^a   Armstrong, Paul W ^b   Califf, Robert M ^c   Johnston, Nina ^a   Simoons, Maarten L ^d   Venge, Per ^a   James, Stefan K ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute coronary syndrome; Inflammatory biomarkers; Mortality; Outcome prediction; Pentraxin 3

Indexed keywords

ABCIXIMAB; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; PENTRAXIN 3; TROPONIN T;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; INFLAMMATORY BIOMARKERS; MORTALITY; OUTCOME PREDICTION; PENTRAXIN 3;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LINEAR MODELS; MALE; PROGNOSIS; SERUM AMYLOID P-COMPONENT; SWEDEN;

EID: 84886381012     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.08.014     Document Type: Article

References (22)

1. Casas J.P., Shah T., Hingorani A.D., Danesh J., Pepys M.B. C-reactive protein and coronary heart disease: a critical update. J Intern Med 2008, 264:295-314.
2. Presta M., Camozzi M., Salvatori G., Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007, 11:723-738.
3. Mantovani A., Garlanda C., Doni A., Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008, 28:1-13.
4. Norata G.D., Marchesi P., Pulakazhi Venu V.K., Pasqualini F., Anselmo A., Moalli F., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
5. Peri G., Introna M., Corradi D., Iacuitti G., Signorini S., Avanzini F., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
6. Salio M., Chimenti S., De Angelis N., Molla F., Maina V., Nebuloni M., et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008, 117:1055-1064.
7. Latini R., Maggioni A.P., Peri G., Gonzini L., Lucci D., Mocarelli P., et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
8. Brügger-Andersen T., Pönitz V., Kontny F., Staines H., Grundt H., Sagara M., et al. The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain. Thromb Haemost 2009, 102:555-563.
9. Matsui S., Ishii J., Kitagawa F., Kuno A., Hattori K., Ishikawa M., et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010, 210:220-225.
10. Simoons M.L., GUSTO IV-ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001, 357:1915-1924.
11. Ottervanger J.P., Armstrong P., Barnathan E.S., Boersma E., Cooper J.S., Ohman E.M., et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. One-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) trial. Circulation 2003, 107:437-442.
12. James S.K., Siegbahn A., Armstrong P., Barnathan E., Califf R., Simoons M.L., et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J 2004, 147:267-274.
13. Johnston N., Jernberg T., Lindahl B., Lindbäck J., Stridsberg M., Larsson A., Wallentin L., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004, 37:210-216.
14. Inoue K., Sugiyama A., Reid P.C., Ito Y., Miyauchi K., Mukai S., et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007, 27:161-167.
15. Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
16. Levey A.S., Greene T., Kusek J.W., Beck G.J., MDRD Study Group A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000, 11:155A.
17. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
18. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
19. Jylhävä J., Haarala A., Kähönen M., Lehtimäki T., Jula A., Moilanen L., et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011, 164:211-217.
20. Dubin R., Li Y., Ix J.H., Shlipak M.G., Whooley M., Peralta C.A. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012, 163:274-279.
21. Latini R., Gullestad L., Masson S., Nymo S.H., Ueland T., Cuccovillo I., et al. Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012, 14:992-999.
22. Yamasaki K., Kurimura M., Kasai T., Sagara M., Kodama T., Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009, 47:471-477.